<DOC>
	<DOCNO>NCT00740051</DOCNO>
	<brief_summary>Efficacy BI 1356 compare placebo patient metformin therapy inappropriate ( intolerability , contraindication ) . The second part study look safety BI 1356 patient population long term treatment comparison sulfonylurea drug ( glimepiride )</brief_summary>
	<brief_title>A Randomised , db , Placebo-controlled Study BI 1356 18 Weeks Followed 34 Week Double-blind Extension Period ( Placebo Patients Switched Glimepiride ) Type 2 Diabetic Patients Whom Treatment With Metformin Inappropriate</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion Patients 18 80 year old type 2 diabetes insufficient glycemic control ( HbA1c 7 % 10 % ) metformin therapy inappropriate ( intolerability contraindication ) Exclusion criterion Myocardial infarction , stroke Transient ischaemic attack last 6 month Treatment rosiglitazone pioglitazone , GLP1 analogues , insulin antiobesity drug past 3 month Impaired hepatic function Severe renal impairment current treatment systemic steroid change dosage thyroid hormone hereditary galactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>